1️⃣ Angelini is buying a US rare disease platform
Angelini agreed on May 7 to buy Catalyst for about $4.1B, or $31.50 per share in cash, adding Firdapse, Agamree and US rights to Fycompa.
💡 Why it matters
This is not pipeline optionality. It gives a European CNS player an operating US rare disease business, with commercial infrastructure and a cleaner route to scale.
☕ Coffee talk
If the US platform is worth $4.1B, how many mid-sized European pharmas are still pretending they can build one slowly?
2️⃣ FDA just reopened the Ebvallo evidence question
Atara said the FDA agreed after a Type A meeting that a single-arm study with an appropriate historical control could support a future tab-cel application for EBV+ PTLD.
💡 Why it matters
That softens the hard line from the January CRL and matters beyond Atara. For ultra-rare cell therapies, the fight is often less about biology than what evidence FDA will still accept.
☕ Coffee talk
Was the January rejection a standard reset, or just a bad CBER moment being quietly unwound?
3️⃣ FDA is testing lighter-touch inspections
FDA launched a pilot for one-day inspectional assessments across areas including biologics, medical products and clinical research, with about 46 assessments completed by late April.
💡 Why it matters
Shorter assessments could widen surveillance without burning full inspection capacity. For sponsors and manufacturers, the practical question is whether this becomes faster feedback or just another pre-inspection signal.
☕ Coffee talk
If a one-day visit finds something awkward, how quickly does “lighter touch” turn into a real inspection?